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Rapid COVID-19 vaccine rollout: immense success but 
challenges ahead
In The Lancet Infectious Diseases, Eric Haas and 
colleagues1 estimated the benefits of the rapid mass 
roll-out of the Pfizer–BioNTech vaccine in Israel 
between Dec 20, 2020, and April 10, 2021. They 
found substantial benefits of the vaccine in terms of 
preventing thousands of deaths, hospitalisations, 
and new SARS-CoV-2 infections in individuals aged 
16 years and older.1 Thanks to the successful vaccination 
programme, non-pharmaceutical restrictions were 
gradually lifted in Israel in February–March, 2021,1,2 and 
the national economy is reported to have recovered in 
April–June 2021, with an estimated economic growth of 
more than 5·5% forecasted for 2021.3
The mass COVID-19 vaccination roll-out in Israel 
has been followed with great interest internationally 
because it was the fastest roll-out globally, and 
achieved high levels of vaccine uptake within a few 
months.1 The vaccination programme was introduced 
at the beginning of a new outbreak wave in Israel in 
December, 2020, when the alpha (B.1.1.7) variant was 
predominant.1,2 The authors report that nearly 74% of 
individuals aged 16 years or older in Israel had received 
two vaccine doses by April 10, 2021,1 increasing to 
81% by June 1, 2021.2 Despite a new outbreak wave 
caused by the delta (B.1.617.2) variant in Israel, with case 
numbers in August, 2021, being at similar levels to those 
in October, 2020, and January, 2021,4 the number of new 
cases are not translating into similar numbers of deaths.4 
This situation underlines the continued importance 
of individuals being fully vaccinated despite emerging 
variants, which is also supported by the experience of 
other countries with high uptake of COVID-19 vaccines, 
like the UK.4
Haas and colleagues found that, when they looked at 
the direct benefits of vaccination, COVID-19 vaccines 
were far more effective at preventing deaths than mild 
infections.1 Other countries have also seen substantial 
decreases in mortality after the introduction of 
COVID-19 vaccination programmes, which have shifted 
the disease burden from mortality to morbidity.5 
Combined with the growing concern about COVID-19 
cases with persistent symptoms (often called long 
COVID), this shift in the disease burden highlights the 
need to better understand non-fatal COVID-19 and its 
effects on health-related quality of life. Notably, Israel 
started vaccinating individuals aged 12–15 years in 
June, 2021,2 who are at lower risk of COVID-19-related 
mortality than older individuals.
The study excluded individuals with previous laboratory-
confirmed SARS-CoV-2 infection.1 By Jan 1, 2021, more 
than 400 000 individuals were reported to have recovered 
from COVID-19 in Israel.2 Hence, the direct benefits of 
the vaccination programme are a conservative estimate 
because previous infection does not guarantee perfect 
protection, and one dose of the Pfizer–BioNTech vaccine 
after a previous SARS-CoV-2 infection leads to similar 
antibody levels as two vaccine doses.6
Additionally, the effect of COVID-19 vaccination 
extends beyond the direct benefits of the vaccination 
programme, with reductions in COVID-19 cases being 
reported in all age groups and among unvaccinated 
individuals in Israel.2 Haas and colleagues acknowledge 
that the indirect effects and the long-term benefits 
of vaccination were outside the scope of the analysis.1 
Additional indirect benefits that have been reported 
elsewhere include the alleviated effect of COVID-19 
on the mental health of health-care workers and the 
general public,7,8 the recovery of the national economy,3 
and freeing up vital resources like hospital beds and staff 
for other patients without COVID-19.
Challenges remain and new challenges will 
undoubtedly continue to arise. For instance, more 
variants are likely to emerge that increase the potential 
for breakthrough infections in vaccinated individuals, 
which will force manufacturers to adapt the vaccines. 
Similarly, in light of newly emerging variants, the 
duration of vaccine-induced protection against both 
symptomatic disease and asymptomatic infection 
is unclear, raising questions of the need for (and 
appropriateness of) regular booster doses (which 
started to be offered in Israel in August, 2021).9 Many 
countries also use different COVID-19 vaccine dosing 
intervals from the officially licensed interval used 
in Israel, and combine different vaccine products in 
the national vaccination programmes, including in 
heterologous vaccination schedules. From a global 
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perspective, other issues outside the scope of this 
Article1 are vaccine equity, access, and affordability.10 
Despite the challenges ahead, Haas and colleagues’ 
research documents the immense success that rapid 
COVID-19 vaccine roll-out had in terms of reducing 
COVID-19-related morbidity and mortality at the 
population level.
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